592 related articles for article (PubMed ID: 26774053)
21. Surface membrane antigen alteration on blood basophils in patients with Hymenoptera venom allergy under immunotherapy.
Siegmund R; Vogelsang H; Machnik A; Herrmann D
J Allergy Clin Immunol; 2000 Dec; 106(6):1190-5. PubMed ID: 11112905
[TBL] [Abstract][Full Text] [Related]
22. The adhesion molecule ICAM-1 is overexpressed in patients with Hymenoptera venom allergy and decreases after ultrarush venom immunotherapy.
Patella V; Incorvaia C; Ricciardi L; Florio G; Saija A; Frati F; Gangemi S
J Biol Regul Homeost Agents; 2011; 25(3):465-8. PubMed ID: 22023772
[TBL] [Abstract][Full Text] [Related]
23. The sting challenge test in Hymenoptera venom allergy: pros and cons.
Bilò MB; Brianzoni MF; Garritani MS; Antonicelli L; Farabollini B; Bonifazi F
Eur Ann Allergy Clin Immunol; 2003 Dec; 35(10):377-81. PubMed ID: 14768522
[TBL] [Abstract][Full Text] [Related]
24. Venom immunotherapy for preventing allergic reactions to insect stings.
Boyle RJ; Elremeli M; Hockenhull J; Cherry MG; Bulsara MK; Daniels M; Oude Elberink JN
Cochrane Database Syst Rev; 2012 Oct; 10(10):CD008838. PubMed ID: 23076950
[TBL] [Abstract][Full Text] [Related]
25. Safety of Ultrarush Venom Immunotherapy: Comparison Between Children and Adults.
Nittner-Marszalska M; Cichocka-Jarosz E; Małaczyńska T; Kraluk B; Rosiek-Biegus M; Kosinska M; Pawłowicz R; Lis G
J Investig Allergol Clin Immunol; 2016; 26(1):40-7. PubMed ID: 27012015
[TBL] [Abstract][Full Text] [Related]
26. Basophil sensitivity in patients not responding to venom immunotherapy.
Peternelj A; Silar M; Erzen R; Kosnik M; Korosec P
Int Arch Allergy Immunol; 2008; 146(3):248-54. PubMed ID: 18270492
[TBL] [Abstract][Full Text] [Related]
27. Prevalence of Hymenoptera venom allergy and its immunological markers current in adults in Poland.
Nittner-Marszalska M; Liebhart J; Liebhart E; Dor A; Dobek R; Obojski A; Medrala W
Med Sci Monit; 2004 Jul; 10(7):CR324-9. PubMed ID: 15232507
[TBL] [Abstract][Full Text] [Related]
28. Specific ultrarush desensitization in Hymenoptera venom-allergic patients.
Schiavino D; Nucera E; Pollastrini E; De Pasquale T; Buonomo A; Bartolozzi F; Lombardo C; Roncallo C; Patriarca G
Ann Allergy Asthma Immunol; 2004 Apr; 92(4):409-13. PubMed ID: 15104191
[TBL] [Abstract][Full Text] [Related]
29. Elevated and cross-responsive CD1a-reactive T cells in bee and wasp venom allergic individuals.
Subramaniam S; Aslam A; Misbah SA; Salio M; Cerundolo V; Moody DB; Ogg G
Eur J Immunol; 2016 Jan; 46(1):242-52. PubMed ID: 26518614
[TBL] [Abstract][Full Text] [Related]
30. Hymenoptera Venom Allergy: How Does Venom Immunotherapy Prevent Anaphylaxis From Bee and Wasp Stings?
Sahiner UM; Durham SR
Front Immunol; 2019; 10():1959. PubMed ID: 31497015
[TBL] [Abstract][Full Text] [Related]
31. [Allergic reactions to insect bites].
Urbanek R
Ther Umsch; 1989 Sep; 46(9):654-62. PubMed ID: 2678576
[TBL] [Abstract][Full Text] [Related]
32. [The basophilic histamine liberation test as a diagnostic method in Hymenoptera venom allergy].
Przybilla B; Ring J; Wielgosch J
Hautarzt; 1988 Oct; 39(10):662-70. PubMed ID: 2466814
[TBL] [Abstract][Full Text] [Related]
33. Adverse reactions to venom immunotherapy.
Ramirez DA; Londono S; Evans R
Ann Allergy; 1981 Dec; 47(6):435-9. PubMed ID: 7325415
[TBL] [Abstract][Full Text] [Related]
34. Prevalence and clinical relevance of specific immunoglobulin E to pollen caused by sting- induced specific immunoglobulin E to cross-reacting carbohydrate determinants in Hymenoptera venoms.
Kochuyt AM; Van Hoeyveld EM; Stevens EA
Clin Exp Allergy; 2005 Apr; 35(4):441-7. PubMed ID: 15836751
[TBL] [Abstract][Full Text] [Related]
35. Humoral immunological response in patients with venom allergy during specific immunotherapy.
Szymański W; Chyrek-Borowska S
Rocz Akad Med Bialymst; 1995; 40(2):376-82. PubMed ID: 8834621
[TBL] [Abstract][Full Text] [Related]
36. Analysis of safety, risk factors and pretreatment methods during rush hymenoptera venom immunotherapy.
Gorska L; Chelminska M; Kuziemski K; Skrzypski M; Niedoszytko M; Damps-Konstanska I; Szymanowska A; Siemińska A; Wajda B; Drozdowska A; Jutel M; Jassem E
Int Arch Allergy Immunol; 2008; 147(3):241-5. PubMed ID: 18594155
[TBL] [Abstract][Full Text] [Related]
37. Safety and efficacy of a 12-week maintenance interval in patients treated with Hymenoptera venom immunotherapy.
Kochuyt AM; Stevens EA
Clin Exp Allergy; 1994 Jan; 24(1):35-41. PubMed ID: 8156444
[TBL] [Abstract][Full Text] [Related]
38. Regulatory T cells in children undergoing rush venom immunotherapy.
Ajduk J; Turkalj M; Gagro A
Allergy Asthma Proc; 2012; 33(6):525-30. PubMed ID: 23394512
[TBL] [Abstract][Full Text] [Related]
39. [Clinical and biological surveillance after the cessation of Hymenoptera venom desensitization].
Touraine F; Talayrach D; Florea O; Brianchon Ch; Preux PM; Bonnaud F
Eur Ann Allergy Clin Immunol; 2003 Nov; 35(9):335-9. PubMed ID: 14716961
[TBL] [Abstract][Full Text] [Related]
40. Safety of specific immunotherapy using a four-hour ultra-rush induction scheme in bee and wasp allergy.
Roll A; Hofbauer G; Ballmer-Weber BK; Schmid-Grendelmeier P
J Investig Allergol Clin Immunol; 2006; 16(2):79-85. PubMed ID: 16689180
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
